As of January 23, 2025, Elevation Oncology (ELEV) has a market cap of $39.610 million USD. According to our data, Elevation Oncology is ranked No.8287 in global market value.
Year | Market Cap | %Change |
---|---|---|
Jan 23, 2025 | $39.61 M |
19.01%
|
Dec 31, 2024 | $33.28 M |
4.84%
|
Dec 29, 2023 | $31.75 M |
-43.47%
|
Dec 30, 2022 | $56.16 M |
-84.22%
|
Dec 31, 2021 | $0.36 B |
100%
|
Name | Market Cap | Market cap difference | Regions |
---|---|---|---|
Blueprint Medicines
BPMC
|
$7.06 B |
-0.000 M
|
USA
|
Deciphera Pharmaceuticals
DCPH
|
$2.21 B |
2.213 B
|
USA
|
Kura Oncology
KURA
|
$0.61 B |
0.000 M
|
USA
|
Relay Therapeutics
RLAY
|
$0.82 B |
0.000 M
|
USA
|
Revolution Medicines
RVMD
|
$7.56 B |
0.000 M
|
USA
|
Zymeworks
ZYME
|
$1.01 B |
-0.000 M
|
Canada
|
Cogent Biosciences
COGT
|
$0.91 B |
-0.000 M
|
USA
|
Foghorn Therapeutics
FHTX
|
$0.24 B |
0.000 M
|
USA
|
G1 Therapeutics
GTHX
|
$0.38 B |
0.000 M
|
USA
|
Arcus Biosciences
RCUS
|
$1.23 B |
-0.000 M
|
USA
|
Iovance Biotherapeutics
IOVA
|
$1.83 B |
-0.000 M
|
USA
|
Market Cap | = | ELEV Stock Price | * | ELEV Shares Outstanding |
= | $0.67 | * | 59.12 M | |
= | $39.61 M |